General practitioners are in a prime position to screen and diagnose common comorbidities of psoriasis and have the experience and knowledge to manage them accordingly.

This article uses lived experience to outline some of the crucial trigger points where support from the general practitioner can have a significant impact on a positive path forward for the patient.

A man aged 35 years with a 14-pack year history of smoking presented to his general practitioner with a 12-month history of progressive dyspnoea.

There is room for improvement in monitoring patients with early chronic kidney disease when considering alignment with national guidelines.

This paper describes a clinical approach to chronic respiratory disorders for clinicians working with Aboriginal and Torres Strait Islander people, particularly in the remote Australian context.

With the advent of new treatments, the outcomes of myeloma have changed drastically in the past decade.

This paper provides an overview of exercise care in general practice to support sustained solutions for patients living with chronic disease.

The Focus articles in this issue explore COVID-19 renal disease, acute kidney injury, renal colic, paediatric urinary tract infections and haematuria.

The interface of general practice and kidney healthcare has never been more important than it is in our current pandemic world.

Patients can be empowered through understanding chronic kidney disease as not confined to a single organ system but as the antecedent and consequence of several pathophysiological processes.

The Focus articles in this issue explore various aspects of chronic kidney disease, as well as cystitis symptoms in women.

Psychological support provided by GPs is an important factor for the maintenance of a positive sense of wellbeing for patients with persistent pain.

Chronic non-cancer pain management illustrates the case for reconceptualising chronic condition management using a generic lifestyle-based approach.

The majority of referrals to a regional outpatient nephrology service contained insufficient detail to meet Australian guidelines.

This article aims to provide evidence-based information to GPs, aiding the decision to initiate sodium–glucose cotransporter 2 (SGLT2) inhibitors for chronic kidney disease patients.